Afghanistan vs Lebanon: Average cost of multi drug-resistant tuberculosis treatment
Afghanistan
1,000 constant 2022 US$
in 2024
Lebanon
1,020 constant 2022 US$
in 2024
Afghanistan rank
48th
Lebanon rank
47th
Average cost of multi drug-resistant tuberculosis treatment over time
- Afghanistan
- Lebanon
How they compare
Lebanon currently reports 1,020 constant 2022 US$ against 1,000 constant 2022 US$ in Afghanistan, a difference of 20 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Lebanon ahead.
Afghanistan ranks 48th and Lebanon ranks 47th of 92 countries.
Lebanon has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,300 constant 2022 US$ | 1,443 constant 2022 US$ | 143 constant 2022 US$ | Lebanon |
| 2020s | 1,000 constant 2022 US$ | 1,227 constant 2022 US$ | 226.6 constant 2022 US$ | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Afghanistan or Lebanon?
- Lebanon, at 1,020 constant 2022 US$ against 1,000 constant 2022 US$ in Afghanistan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Afghanistan and Lebanon?
- 20 constant 2022 US$, with Lebanon ahead.
- How many years of comparable data are there for Afghanistan and Lebanon?
- 8 years are reported by both, from 2017 to 2024.
- How do Afghanistan and Lebanon rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Afghanistan ranks 48th and Lebanon ranks 47th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.